Saneca Pharma, a Slovakia-based contract development and manufacturing organisation (CDMO), has renewed its agreement with Pharmascience Inc. for the manufacture and supply of prescription medicines in tablet form. Pharmascience is one of Canada’s largest pharmaceutical companies.
The extension of the agreement follows a successful GMP audit held in January 2018.
As part of the agreement, Saneca is set to manufacture 600 million enteric, chewable and film-coated tablets (RX medicines) per year. The agreement will also involve R&D and laboratory analyses related to existing and emerging formulations, as well as technical support for delivery to the Canadian market.
“Saneca Pharma produces large number of tablets for customers every year and has a huge amount of expertise, especially in solid dose manufacturing,” said Markus Saal, sales director at Saneca Pharma.
Saal pointed out that by delivering both development and manufacturing services, the company is also able to simplify the tech transfer process to commercial production and streamline our customers’ projects, saving time and costs.
“Pharmascience is a big name in the pharmaceutical industry, so it’s great to work with them on a project of this size. We’re confident we’ll be able to add value to this project by combining our in-depth knowledge and our wide range of capabilities,” he added.
The substantial agreement consists of nine different stock keeping units (SKUs), covering several therapeutic areas.
Pierre Plante, sourcing director at Pharmascience, commented: “Saneca Pharma is well located in Europe and its experience in manufacturing solid dose products was a huge part of the reason we selected them as our outsourcing partner for this project.”
Plante said Seneca’s comprehensive tech-transfer offering was also interesting for the company. “We look forward to continuing to develop our partnership with Saneca as we move into 2018,” he concluded.
